Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: a potential improvement to overall survival and decrease to multivisceral resection
| Autor: | Weiwei Xiao, Qing Liu, Yan Yuan, Wei-Hao Xie, Peiqiang Cai, Yuanhong Gao, Qiaoxuan Wang, Zhifan Zeng, Hui Chang, Wenhao Zhou, Bao-Qing Chen, Xiaojun Wu, Liren Li, Rong Zhang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Colorectal cancer medicine.medical_treatment Organ preservation lcsh:RC254-282 Locally advanced colon cancer Capecitabine Surgical oncology Antineoplastic Combined Chemotherapy Protocols Genetics medicine Humans Adverse effect Aged Neoplasm Staging Chemotherapy Pathological complete response business.industry Incidence (epidemiology) Middle Aged medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Combined Modality Therapy Neoadjuvant Therapy Surgery Radiation therapy Neoadjuvant chemoradiotherapy Survival Rate Regimen Treatment Outcome Oncology Chemotherapy Adjuvant Colonic Neoplasms Quality of Life Female Fluorouracil business medicine.drug Research Article |
| Zdroj: | BMC Cancer BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021) |
| ISSN: | 1471-2407 |
| Popis: | Background The management of unresectable locally advanced colon cancer (LACC) remains controversial, as resection is not feasible. The goal of this study was to evaluate the treatment outcomes and toxicity of neoadjuvant chemoradiotherapy (NACRT) followed with surgery and adjuvant chemotherapy in patients with unresectable radically LACC. Methods We included patients who were diagnosed at our institution, 2010–2018. The neoadjuvant regimen consisted of radiotherapy and capecitabine/ 5-fluorouracil-based chemotherapy. Results One hundred patients were identified. The median follow-up time was 32 months. The R0 resection rate, adjusted nonmultivisceral resection rate and bladder preservation rate were 83.0, 43.0 and 83.3%, respectively. The pCR and clinical-downstaging rates were 18, and 81.0%%, respectively. The 3-year PFS and OS rates for all patients were 68.6 and 82.1%, respectively. Seventeen patients developed grade 3–4 myelosuppression, which was the most common adverse event observed after NACRT. Tumor perforation occurred in 3 patients during NACRT. The incidence of grade 3–4 surgery-related complications was 7.0%. Postoperative anastomotic leakage was observed in 3 patients. Conclusions NACRT followed by surgery was feasible and safe for selected patients with LACC, and can be used as a conversion treatment to achieve satisfactory downstaging, long-term survival and quality of life, with acceptable toxicities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink